ALFA FinderBSE filing, NSE: TATVA. Summary written from the filing by ALFA Finder's alert engine.
Tatva Chintan Pharma Chem Ltd: key numbers
- Share price
- ₹1,605.80
- Market cap
- ₹3,756 Cr
- Revenue (annual)
- ₹505.9 Cr
- Net profit (annual)
- ₹42.05 Cr
- P/E (TTM)
- 59.7×Sector 28.2×
- Promoter holding
- 72.02%+0.00% QoQ
- FII holding
- 4.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tatva Chintan Pharma Chem Ltd
All →Tatva Chintan Pharma Chem Investor Presentation: Key Takeaways
Tatva Chintan reported record quarterly revenue of ₹2,173 Mn for Q2 FY27, up 76% YoY, driven by strong SDA demand. EBITDA margins remained flat at 19% due to high solvent costs and freight spikes.
Tatva Chintan Pharma Chem Q2 FY27 Results: Net Profit ₹21.5 Cr, Up 117.2% YoY
Tatva Chintan Pharma Chem Ltd reported revenue from operations of ₹217.3 Cr (+76.0% YoY) and net profit of ₹21.5 Cr (+117.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹21.5 Cr · +117.2% YoY
Tatva Chintan Pharma Chem Other Announcement
The company has filed its quarterly shareholding pattern as per SEBI regulations. This routine disclosure provides details on the current shareholding structure.
Tatva Chintan Pharma Chem Board Meeting Date
Tatva Chintan Pharma Chem has scheduled a Board meeting for 19 October 2026 to consider Q1 FY27 financial results. The trading window will remain closed until 48 hours after results are published.
Tatva Chintan Pharma Chem Annual General Meeting
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
Tatva Chintan Pharma Chem Credit Rating
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.
Other annual report announcements
All →Generic Engineering Construction and Projects Annual Report
Generic Engineering filed its FY2025-26 Annual Report ahead of its 32nd AGM on 30 November 2026. The filing covers board changes and a planned bank-funded EPC expansion.
Vineet Laboratories Annual Report
Vineet Laboratories filed its FY 2025-26 Annual Report, which marks its turnaround and recapitalisation year. The AGM is scheduled for 30 November 2026.
Indrayani Biotech Annual Report
Indrayani Biotech has filed its 34th Annual Report for FY2025-26, containing the AGM notice for 30 November 2026 by VC/OAVM. The chairman notes a Rights Issue was initiated in October 2026 to raise capital.
ESDS Software Solution Annual Report
ESDS Software Solution submitted its FY2025-26 Annual Report along with the AGM notice. The AGM is on 30 November 2026 via VC/OAVM, with remote e-voting.
The Orissa Minerals Development Company Annual Report
Orissa Minerals Development Company filed its FY 2025-26 Annual Report and 108th AGM notice, with the AGM set for 30 November 2026. The filing is a Regulation 34 intimation with no transaction or financial event.
Viksit Engineering Annual Report
Viksit Engineering filed its 44th Annual Report for FY 2025-26 with BSE. The report includes notice of the AGM on 30 November 2026.